Johns Creek, GANCT05835206Now EnrollingIRB Ready

Antibiotic-Resistant Infection Clinical Trial in Johns Creek, GA

Access cutting-edge antibiotic-resistant infection treatment through this phase 2 clinical trial at a research site in Johns Creek. Study-provided care at no cost to qualified participants.

Sponsored by Emory University

Quick Self-Assessment

See if you qualify for this Johns Creek location

Preparing your pre-screening questions…

Expert Care in Johns Creek

Access antibiotic-resistant infection specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related antibiotic-resistant infection treatment provided free

Apply for This Johns Creek Location

Check if you qualify for this antibiotic-resistant infection clinical trial in Johns Creek, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Johns Creek

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Johns Creek site if eligible
  4. 4Begin participation

About This Antibiotic-Resistant Infection Study in Johns Creek

The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection. Limited data from prior studies suggest that MT may be an effective treatment to reduce intestinal MDRO colonization Although shedding of MDROs from patients to their surrounding environment is a recognized pathway of transmission, the potential effect of MT on the transmission of MDRO to

Sponsor: Emory University

Who Can Participate

Inclusion Criteria

Be able to (or have an available Legally Authorized Representative who is able to) understand and be willing to sign a written informed consent document.
Be at least 18 years old at the time of consent.
Be able and willing to comply with all study protocol requirements, including the ability to swallow capsules.
Be colonized with a target MDRO (CRE, VRE, ESBL, MDR Acinetobacter, and/or MDR Pseudomonas) as detected by bacterial culture of stool or perianal/rectal swab.
Be able and willing to discontinue systemic antibiotics at least one day prior to study Day 0 and for as long as medically able to do so throughout the study.
Be willing to discontinue probiotics or other microbiota restoration therapies at least one day prior to study Day 0 and for the duration of study participation.
The effects of the IP on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

Exclusion Criteria

Be pregnant, breastfeeding, lactating, or planning a pregnancy during the study duration (through 4 weeks after the last dose of investigational product, or IP), if women of childbearing potential (WOCBP).
Have known uncontrolled intercurrent illness(es) such as, but not limited to Symptomatic congestive heart failure, acute coronary syndrome, cardiac arrhythmia, untreated in situ colorectal cancer, toxic megacolon or ileus, use of medications that decrease GI motility and increase broncho-aspiration risk (e.g. loperamide, diphenoxylate/atropine, cholestyramine), or history of positive stool studies or cultures in the last 30 days for ova, parasites, Salmonella, Shigella, Campylobacter, or other enteropathogens other than those detected by screening MDRO stool cultures for inclusion.
Have any other intercurrent acute illness that in the opinion of the investigator will preclude the subject from entering the study.
Be on systemic antibiotics for any reason other than if the MDRO infection was recent or the potential participant is still taking antibiotics for target MDRO at the time of screening. If the latter, the participant must be able (in the opinion of their treating providers) to complete the planned antibiotic course by study Day -1.
Have a compromised immune system, defined as AIDS with a cluster of differentiation 4 (CD4)+ T-cell count \<200, history of documented absolute neutrophil count (ANC) \<1,000 neutrophils/mL within 14 days of D0, active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment within 2 months of enrollment or history of hematopoietic cell transplantation, either allogeneic or autologous in the last 1 year.
Have a history of significant food allergy that led to anaphylaxis or hospitalization.
Have a life expectancy of 24 weeks or less
Have any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to known active intravenous drug or alcohol abuse, psychiatric illness, and/or social situation
Participated in an investigational study that also meets one of the following criteria: Received an interventional agent (drug, device, or procedure) in the last 28 days or enrollment in any other interventional study for MDROs.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Johns Creek?

Yes, this clinical trial (NCT05835206) has an active research site in Johns Creek, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Antibiotic-Resistant Infection Treatment Options in Johns Creek, GA

If you're searching for antibiotic-resistant infection treatment options in Johns Creek, GA, this clinical trial (NCT05835206) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Johns Creek research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced antibiotic-resistant infection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all antibiotic-resistant infection clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Johns Creek, GA

See all interstitial cystitis clinical trials recruiting in Johns Creek — not just this study.

Browse Interstitial Cystitis Trials in Johns Creek →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Johns Creek?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Johns Creek, GA